

16<sup>th</sup> May 2022

# Chrysos increases Total Contract Value to A\$559.8 million with new international customer agreements

## Highlights

- Five new PhotonAssay lease agreements signed, increasing Chrysos' Total Contract Value ("TCV") by A\$108.6m to A\$559.8m
- Total number of deployed or contractually-committed PhotonAssay units rises from 33 to 38
- Three new PhotonAssay leases signed with new customers Alfred H Knight and Britannia Life Sciences, and an additional two PhotonAssay leases signed with existing customer, Intertek
- Two new PhotonAssay units deployed with existing customers MSALABS and ALS, taking the company's deployed unit base to 10
- Barrick Gold expands its adoption of PhotonAssay technology, with one of MSALABS' alreadycommitted PhotonAssay units to be deployed to Barrick's Kibali gold mine in the Democratic Republic of Congo


Chrysos Corporation Limited ("Chrysos" or the "Company") (ASX:C79) is pleased to announce that it has signed five new Chrysos PhotonAssay<sup>™</sup> lease contracts with new and existing customers, bringing the total number of deployed or contractually-committed units to 38, up from the previous total of 33 units.

The new lease contracts increase Chrysos' TCV by A\$108.6m to A\$559.8m (see graph right).<sup>12</sup>

Regarding Chrysos' accelerating growth, Managing Director and Chief Executive Officer Dirk Treasure, stated: "This is an exciting time for our business as we continue to execute our expansion plans and focus on key international mining hubs."

"With increasing demand, a strong pipeline of blue chip customers and our global market penetration continuing at pace, we feel the business is well positioned to meet its ongoing strategic and operational objectives."

Two five-year leases (with five-year renewal



options) have been signed with new customer Canadian-based Britannia Life Sciences ("Britannia") to deploy PhotonAssay units across its newly-formed North American subsidiary, Britannia Mining Solutions ("BMS"). The contract specifies the deployment of an initial two PhotonAssay units whilst providing the opportunity for further expansion of the agreement in the future.

<sup>&</sup>lt;sup>1</sup> TCV is calculated using foreign exchange rates of AUD:USD 0.73, AUD:CAD 0.94 and AUD:GBP 0.56. The USD and CAD rates are based on the average of the 3-month forward curve from Bloomberg in March 2022, per the Chrysos prospectus and GBP rates are based on the average of the 3-month forward curve from Bloomberg in May 2022.

<sup>&</sup>lt;sup>2</sup> TCV represents the future minimum contracted revenue on PhotonAssay leases (both deployed and committed) that are yet to be invoiced at a point in time, which are subject to the Company's contractual performance obligations and where the Directors consider reasonable certainty exists, may include values associated with exercise of option periods.



Two other new lease contracts highlight Chrysos' growing relationship with international testing, inspection and certification company, Intertek ("ITK"). The association, which started with the installation in 2021 of two PhotonAssay units at ITK's Minerals Global Centre of Excellence in Perth, Western Australia has since expanded to include another already-operating unit in Perth and the upcoming deployment of two new units on a five-year plus five-year-option contract basis for the ITK business in Ghana.

Chrysos is also pleased to announce one recently-comissioned PhotonAssay unit is now operating in Val d'Or, Canada with MSALABS, and another unit is now fully-operational in Kalgoorlie, Australia with ALS.

Furthermore, Barrick Gold is expanding its adoption of PhotonAssay technology, with one of MSALABS' already-committed PhotonAssay units to be deployed to Barrick's Kibali gold mine in the Democratic Republic of Congo.

### ENDS

### About Chrysos Corporation

Headquartered in Adelaide, with operations spanning Australia, Canada and Africa, Chrysos Corporation combines science and software to create technology solutions for the global mining industry. The Company's flagship product PhotonAssay delivers faster, safer, more accurate and environmentally-friendly analysis of gold, silver, copper and other elements. For more information about Chrysos or its PhotonAssay technology, visit <u>www.chrysos.com.au</u>.

### For enquiries, please contact:

Catherine Strong	Citadel-MAGNUS	+61 406 759 268	<u>cstrong@citadelmagnus.com</u>
Maddie Seacombe	Citadel-MAGNUS	+61 402 999 291	<u>mseacombe@citadelmagnus.com</u>
Chrysos Investor Relations		+61 8 7078 4571	<u>investors@chrysos.com.au</u>

This announcement was authorised for release by the Board of Chrysos Corporation Limited.